Recalled Artificial Tears Eye Drops Linked to Deadly Infections were Never Tested by FDA: Bloomberg Reports

Many over-the-counter products in the U.S., like the recently recalled Artificial Tears eye drops, are allowed to be sold to consumers on a sort of "honor system", according to the report.

Federal regulators announced an Artificial Tears eye drops recall earlier this year, after reports surfaced involving dozens of severe eye infections caused by bacterial contamination, including cases that resulted in eyeball removals, blindness and fatal infections. However, a recent report highlights how the imported eye drops were allowed into the country without any testing or inspection.

The recalled Artificial Tears eye drops have been found to contain Carbapenem-Resistant Pseudomonas Aeruginosa (CRPA), which is bacteria that may result in infections resulting in mild to severe health consequences, including fever, chills, body aches, light-headedness, rapid pulse, heavy breathing, nausea and vomiting, diarrhea, and decreased urination.

The strain of Pseudomonas aeruginosa linked to recalled Artificial Tears eye drops poses a major health risk due to its antibiotic resistance and capability of mutating quickly. In severe cases, Pseudomonas aeruginosa may cause endophthalmitis, which is a rare but serious infection of the eyeball that can cause inflammation and destruction of the tissue throughout the eye, resulting in irreversible blindness.

While the manufacturers now face a growing number of Artificial Tears recall lawsuits being pursued by individuals left with devastating injuries, the federal regulatory system is also coming under scrutiny, and questions are being asked about how contaminated eye drops were able to be so widely distributed and sold in the U.S. before the problems were discovered.


Did you or a loved one use recalled eye drops?

Lawyers are investigating EzriCare Artificial Tears lawsuits for individuals who experienced eye infections, blindness or other problems following use of the recalled eye drops.


Last week, a comprehensive investigative report was published by Bloomberg News (subscription required), highlighting how the U.S. Food and Drug Administration never tested the products and never inspected the overseas manufacturing facility where the eye drops were made.

Over-the-Counter Drugs Allowed into U.S. on “Honor System”

According to Bloomberg, under current regulations, many over-the-counter products sold to U.S. consumers do not require manufacturers to provide evidence establishing that they are safe or effective. In addition, manufacturers are not always required to undergo FDA inspections of their production facilities or packaging plants before they can be widely distributed to Americans.

All a company has to do is tell the FDA that it is using the approved ingredients and following good manufacturing practices. The agency does not check to see if the manufacturer’s claims are true until there is a problem, relying on a form of honor system.

In the case of Artificial Tears eye drop recall, two U.S. businessmen, neither of whom had ever sold a drug product before, hired Global Pharma Healthcare Pvt, Ltd. in Chennai, India to manufacture the eye drops, selling them under the separate Ezricare and Delsam Pharma labels. However, Global Pharma had no experience ever exporting a drug to the U.S., particularly one which had to be sterile, meaning it had never had to meet FDA standards with any of its previous products.

Despite that, the FDA allowed the product to be shipped to the U.S. and sold in pharmacies nationwide, as well as through and other on-line retailers.

The report highlights major failings of the FDA’s “honor system”, suggesting that the agency should have noticed the inexperience of the manufacturers involved, and the fact that the eye drops were being marketed as “preservative free,” which meant they lacked certain ingredients that are used to prevent the growth of bacterial contaminants.

FDA officials say they are trying to improve their automated systems to monitor and screen products. However, the generic drug market is growing too rapidly for the agency to keep up, Bloomberg News reported. Such improvements may require significant increases in funding, restructuring, and staff, experts say.

Artificial Tears Eye Drops Lawsuits

The U.S. Centers for Disease Control and Prevention (CDC) has been tracking infections linked to recalled Artificial Tears eye drops, indicating in May that the agency was aware of at least 81 infections in 18 different states.

In addition to four deaths linked to severe infections caused by the eye drops, the CDC indicates a number of other cases involved hospitalization or individuals who suffered vision loss, with at least another four cases resulting in the need for surgical eye removal.

As the number of reported eye drops infections continue to rise, a series of lawsuits have been filed against the manufacturers, claiming they failed to perform proper microbial testing, allowing the products to be sold directly to consumers containing Pseudomonas aeruginosa.

Lawyers are actively investigating potential eye drop infection lawsuits against the manufacturers and distributors of EzriCare and Delsam Pharma’s eye drops for multiple injuries and side effects caused by the contamination, including;

  • Eye Infection
  • Partial Blindness
  • Permanent Blindness
  • Bloodstream Infection
  • Other injuries caused by the eye drops


  • SharonJuly 26, 2023 at 7:57 am

    I need drops for my eyes I am terrified of using any drops now I cherish what vision I have now bad lasik surgery gone wrong and 13 surgeries later I just don't want to put anything in them I have gotten a bacterial infection that memics pink eye it was nasty from drops

  • DonnaJuly 25, 2023 at 3:25 pm

    Developed Pink Eye after using Artificial Tears.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.